Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash & Equivalents (2016 - 2025)

Iradimed (IRMD) has disclosed Cash & Equivalents for 13 consecutive years, with $56.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 9.29% to $56.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $56.5 million, a 9.29% increase, with the full-year FY2024 number at $52.2 million, up 4.97% from a year prior.
  • Cash & Equivalents was $56.5 million for Q3 2025 at Iradimed, up from $53.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $62.0 million in Q4 2021 to a low of $42.8 million in Q1 2023.
  • A 5-year average of $51.8 million and a median of $51.7 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: rose 23.83% in 2021, then dropped 15.91% in 2023.
  • Iradimed's Cash & Equivalents stood at $62.0 million in 2021, then fell by 6.51% to $58.0 million in 2022, then fell by 14.15% to $49.8 million in 2023, then grew by 4.97% to $52.2 million in 2024, then grew by 8.22% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Cash & Equivalents are $56.5 million (Q3 2025), $53.0 million (Q2 2025), and $50.3 million (Q1 2025).